What Валокордин Treats: Main Uses and Benefits

Валокордин (Valocordin) is commonly used for managing symptoms where supportive relief may be appropriate for adult patients experiencing functional discomfort often rooted in nervous system over-excitation, aligning its benefits across three core therapeutic areas. This is relevant in contexts marked by increased discomfort or tension, as its components are associated with symptomatic relief across key domains.

The preparation is used for managing symptom clusters related to nervous tension, heightened irritability, episodic sleep disturbances, and functional physical tension (e.g., mild heart awareness or spasms). It is commonly applied in scenarios where patients experience increased discomfort or tension, such as during phases of situational stress or overwork.

“The preparation is considered relevant in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is appropriate.”

The supportive assistance may help maintain a sense of stability, which assists with promoting relaxation and supports patients during episodes of heightened discomfort. It may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Nervous Tension
Applies to: Symptoms of irritability, restlessness, and edginess that interfere with daily comfort.
Benefit: Contributes to easing the overall symptom load by dampening central nervous system over-excitation during episodes of heightened discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Who Can and Cannot Use Валокордин?

The eligibility for using Валокордин is strictly defined by regulatory documents, which establish clear restrictions and absolute prohibitions based on specific patient conditions and physiological status.

Populations for Whom Use is Prohibited (Contraindications)

Official regulatory labeling mandates that the medicine must not be used by the following groups:

• Pregnancy and Breastfeeding: Use is strictly contraindicated during pregnancy and in mothers who are breastfeeding.
• Age: The medicine is contraindicated in children and adolescents under 18 years of age.
• Organ Impairment: Patients with severe hepatic insufficiency (severe liver failure) or severe renal insufficiency (severe kidney failure) are explicitly excluded from use.
• Hypersensitivity: Individuals with a known or suspected hypersensitivity (allergic reaction) to any of the drug's active ingredients or excipients are strictly prohibited from using it.

Summary of Eligibility

The official eligibility profile is structured by these absolute prohibitions. Only the adult population not affected by these contraindications is considered eligible for use. The regulatory documents define eligibility constraints based on a patient's age, reproductive status, and the functional integrity of their liver and kidneys.

Interactions with other medicines and products

The official interaction profile for Валокордин is primarily defined by the component Phenobarbital, which is documented in regulatory sources as both a central nervous system (CNS) depressant and a potent inducer of hepatic microsomal enzymes (CYP450 system).

Formal Contraindicated Combinations

Co-administration is formally prohibited with specific agents to prevent severe outcomes. The regulatory label lists Opioids and Sodium Oxybate as contraindicated due to the high risk of severe, additive CNS and respiratory depression. Certain Antivirals and Hormonal Contraceptives are also contraindicated, as the induction effect significantly reduces their plasma exposure, potentially leading to therapeutic failure.

Documented Pharmacokinetic Effects

As a potent enzyme inducer, the preparation reduces the efficacy and clearance of numerous co-administered drugs. This effect causes decreased plasma concentrations for agents such as Oral Anticoagulants (e.g., Warfarin, Dicumarol), Corticosteroids, and Doxycycline. Conversely, the exposure of the preparation’s component is documented to increase when co-administered with inhibitors of its metabolism, such as Monoamine Oxidase Inhibitors (MAOIs) or Valproic Acid derivatives.

Pharmacodynamic and Timing Constraints

The label notes additive CNS depressant effects when the preparation is taken with Alcohol or other sedating medicines, including antihistamines or hypnotics. Furthermore, due to the sustained enzyme induction, official documentation mandates a separation period of at least 28 days following the preparation’s discontinuation before relying on certain hormonal contraceptives.

The combined action of Valocordin's primary components modulates both central nervous and peripheral systems. The drug's influence is characterized by two main mechanistic domains.***

Modulation of GABA A Receptor Activity

Phenobarbital, a barbiturate component, acts within the central nervous system (CNS) as an allosteric modulator of the gamma-aminobutyric acid ( GABA A) receptor, which is the principal inhibitory neurotransmitter system. Binding to a distinct site on the receptor complex, phenobarbital increases the duration of chloride ion channel opening. This action promotes chloride influx into the neuron, leading to neuronal hyperpolarization and a subsequent reduction in overall CNS excitability.

Central Depression and Antispasmodic Effect

The GABA A potentiation cascade induces generalized CNS depression and elevates the action potential threshold, resulting in reduced neural activity. Concurrently, ethyl alpha-bromoisovalerate contributes to this cascade through associated central nervous system depressant activity. Additionally, this component is associated with a mild antispasmodic action on smooth muscles, including those in the vasculature and gastrointestinal tract. This peripheral effect modulates processes associated with heightened mediator activity, leading to the attenuation of localized overactive physiological responses, such as vascular and intestinal tension.

Official Administration Guidelines for Валокордин

Валокордин is an oral solution (drops) that must be administered strictly according to the procedures outlined in regulatory documentation to ensure correct dosing and administration. The instructions detail the required preparation, dose measurement, and administration schedule.

Administration Scope	Instruction
Route of Administration	Oral (internal use) only.
Dosage Form	Oral drops (liquid solution).

---

Dosing Rules and Frequency

Official instructions specify the dose in drops and require adherence to both single-dose and total daily maximum limits:

• Standard Single Dose: The typical single dose for an adult is 15 to 20 drops.
• Frequency: The medicine is generally taken two or three times per day, with specific scheduling determined by the prescribing physician.
• Maximum Daily Dose: Patients must not exceed the specified maximum recommended total dose per 24 hours (e.g., 40 to 60 drops), as excessive dosing may carry risks due to the phenobarbital component.
• Duration of Use: The overall length of treatment is not standardized but must be individually determined and managed by a healthcare provider, avoiding prolonged, unsupervised use.

---

Preparation and Special Conditions

• Preparation: The prescribed number of drops must be diluted with a small amount of liquid (e.g., 30 to 50 mL of water) before being swallowed.
• Measurement: Use the dispensing bottle's integrated dropper device to accurately measure the precise number of drops for each dose.
• Age-Specific Dosing: Dosage adjustments, typically a reduction, may be required for elderly or debilitated patients.

---

Summary of Use Protocol: The official protocol requires precise measurement, dilution in water, and adherence to a strict, multi-dose daily schedule, all defined by professional guidance.

Research evidence / Overview of studies for Валокордин

Overview of Studies for Nervous Tension and Functional Discomfort

The research landscape for this combination preparation was observed in studies exploring various data types. The product was studied for how symptoms change over time in periods of heightened symptom activity, such as nervous over-excitation and functional physical tension. Research examined outcomes related to patient-reported experiences of tension, restlessness, and the self-reported quality of repose. The studies monitored in the available literature largely represent observational settings evaluating daily-life functioning and contribute to understanding symptom patterns rather than relying on large-scale, placebo-controlled trials.

The Nature of Available Research and Study Designs

The overall body of evidence directly related to the Валокордин combination suggests that the certainty remains low. The research base for the combination drug itself was observed in Review Articles and Observational Studies published in regional scientific literature. These studies report how symptoms evolved in the observed populations over short time frames, capturing patient-reported outcomes describing perceived discomfort. In contrast, the barbiturate component, Phenobarbital, was evaluated in numerous Randomized Controlled Trials (RCTs) and Systematic Reviews for its use in severe neurological conditions. However, these higher-certainty findings do not directly apply to the low-dose combination formulation used in research exploring short-term symptom changes for situational tension.

Duration of Observation and Long-Term Data

The majority of evidence that exists was observed in research exploring short-term symptom changes, relevant in contexts involving episodic or situational symptom patterns. The follow-up durations were limited in many of the available reports. Consequently, the long-term effects are not fully established, and there is limited information for long-term outcomes or how symptoms might be monitored over extended time intervals.

Key Limitations and Areas of Uncertainty

There is a paucity of dedicated, modern, placebo-controlled RCTs specifically focused on the four-component formulation used for nervous tension. The evidence quality varies across studies, often relying on historical or observational findings. Furthermore, sample sizes were modest in much of the available regional research. These factors highlight what is known — and what is still uncertain — about the preparation, suggesting that more dedicated research is ongoing in the broader evidence landscape to provide deeper insight into temporary physiological imbalance and the study of symptom patterns.

Key Studies & References

1. Phenobarbital (StatPearls - National Institutes of Health)
2. Phenobarbital Drug Information (NIH MedlinePlus)

Common questions about Валокордин (FAQ)

---

Q: How does Валокордин differ in composition from similar common sedative drops?

According to the official product information, Валокордин is a unique combination product. Its formulation includes synthetic active ingredients like a barbiturate (Phenobarbital) and a brominated compound (Ethyl bromisovalerinate). This synthetic pairing is blended with natural essential oils, setting its composition apart from simple single-ingredient sedative drops.

---

Q: Are there known interactions between Валокордин and common pain relievers?

Official regulatory documents indicate that this medicine contains an ingredient that is a known enzyme inducer. This means it can speed up the way the liver breaks down certain co-administered drugs. This process may lead to a reduction in the efficacy or blood levels of many co-administered medicines, including various pain relievers.

---

Q: Is there evidence for the use of Валокордин in managing mild insomnia or difficulty sleeping?

The medicine's stated purpose is to relieve nervous tension and support the achievement of restful repose. Additionally, the Phenobarbital component within the drug is classified in regulatory literature for the short-term treatment of insomnia.

---

Q: Why is Валокордин sometimes restricted or banned in certain Western countries?

The restrictions in various jurisdictions are associated with the component Phenobarbital. This substance is classified as a controlled substance in many countries due to its potential for dependence and misuse, which affects the regulatory status of the combination product.

---

Q: Is it possible for Валокордин to impair or affect a person's ability to drive a vehicle?

Regulatory guidance explicitly states that the drug may impair the mental and physical abilities required for performing potentially hazardous tasks. This includes activities such as driving a car or operating machinery.

---

Q: What is the typical shelf life of Валокордин once the bottle has been opened?

While the official labeled expiration date applies to the sealed container, preparations similar to these oral drops are often given limited stability guidelines once opened. For example, a compounded Phenobarbital oral solution is often documented as stable for up to 30 days at room temperature after the first opening.

---

Q: What concerns exist in medical literature regarding the bromide content in the drug?

The preparation contains Ethyl bromisovalerinate, which is a brominated compound. Safety information indicates that chronic use of the product is associated with a risk of developing physical and psychological dependence.

---

Q: How does Валокордин affect people who naturally have low blood pressure?

Safety information documents that the drug may cause effects on the cardiovascular system. Specifically, hypotension (low blood pressure) and bradycardia (slowed heart rate) are noted as possible adverse reactions.

---

Q: What is the typical timeframe for feeling the effect of Валокордин?

Based on the pharmacokinetics of the main component, the onset of action for oral use is typically one hour or longer. The duration of the therapeutic effect may then range between 10 to 12 hours.

---

Q: How might Валокордин interact with common vitamin or mineral supplements?

Official regulatory sources confirm that the drug may reduce the levels of certain vital nutrients in the body. It is known to lower the levels of vitamins such as folate, Vitamin D, and Vitamin K.

---

Q: What are the general guidelines if a person forgets to take an intended dose of Валокордин?

The general regulatory guidance for missed doses of this type of medication suggests skipping the forgotten dose if it is almost time for the next scheduled dose. Official information emphasizes that extra medicine should not be taken to compensate for the missed dose.

---

Q: Does official guidance address using Валокордин alongside medication for high blood pressure?

Official guidance notes that the drug contains an ingredient that can act as a potent enzyme inducer, meaning it may reduce the blood concentration of many co-administered medicines. Furthermore, the drug may also cause hypotension (low blood pressure) as a side effect.

---

Q: Are there specific foods or beverages that are known to interfere with Валокордин?

Regulatory data on the drug's components indicates that the absorption of the Phenobarbital component may be decreased. This occurs if it is taken simultaneously with products containing aluminum salts, such as certain types of antacids.

---

Q: How long does the phenobarbital component of Валокордин typically remain detectable in the body?

Official pharmacokinetic data classifies the drug as a long-acting compound. The plasma half-life of Phenobarbital in adults is lengthy, typically ranging from 53 to 118 hours.

---

Q: Is Валокордин described as having any direct analgesic (pain-relieving) properties?

The preparation is classified as a sedative-hypnotic and antispasmodic agent, used for nervous tension and functional discomfort. Regulatory literature describes its main component as a nonanalgesic hypnotic, meaning it does not primarily function as a pain reliever.

---

Q: What are the officially documented signs and symptoms of taking too much Валокордин (overdose)?

Symptoms of overdose documented in official sources relate primarily to CNS depression. These signs can include slowed or shallow breathing, extremely low blood pressure (shock), decreased level of consciousness leading to coma, confusion, and slurred speech.

---

Q: Can the effectiveness of Валокордин potentially decrease over time with regular use?

Studies and official information indicate that tolerance can develop with continued use of this type of medication. For instance, barbiturates are documented to lose their full effectiveness for sleep induction and maintenance after approximately two weeks of regular use.

---

Q: Does the efficacy of Валокордин change if it is taken with food versus on an empty stomach?

Pharmacokinetic data for the component Phenobarbital indicates that its absorption is faster when the medicine is ingested on an empty stomach. Taking the preparation with food may therefore delay the timeframe for feeling the initial effect.

Storage and Disposal Requirements

The storage and disposal of Валокордин (Valocordin) must strictly adhere to the conditions mandated in the official regulatory labeling to ensure product stability and safety. The drops must be stored at a temperature not exceeding 25°C and must be kept in a place protected from light.

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 25 C.
Protection	Store protected from light.
Child Safety	Keep out of the sight and reach of children.

Maintaining the container closed is required to preserve the product's concentration. The labeled expiration date applies only when these mandated storage conditions are strictly followed. Due to the composition, all unused or expired Валокордин must be disposed of according to local regulations governing pharmaceutical waste.